Feagan BG, Sands BE, Siegel CA, Dubinsky MC, et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol 2025 May 30:S2468-1253(25)00071.
PMID: 40456235